OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.3333.

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of OnKure Therapeutics to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of OnKure Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of OnKure Therapeutics in a research note on Tuesday, August 26th. Finally, Zacks Research cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in OnKure Therapeutics during the second quarter worth $25,000. Bailard Inc. acquired a new position in shares of OnKure Therapeutics during the 2nd quarter worth $34,000. ADAR1 Capital Management LLC bought a new stake in shares of OnKure Therapeutics during the 1st quarter worth $43,000. Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics during the 2nd quarter worth $71,000. Finally, GSA Capital Partners LLP boosted its stake in OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock valued at $163,000 after buying an additional 37,459 shares in the last quarter. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Stock Up 1.1%

OKUR stock opened at $2.86 on Thursday. OnKure Therapeutics has a twelve month low of $1.70 and a twelve month high of $15.89. The company has a market cap of $38.75 million, a P/E ratio of -0.60 and a beta of 0.46. The business has a fifty day moving average of $2.93 and a 200-day moving average of $2.62.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.11. As a group, equities research analysts anticipate that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.